- Title:
Presentation and Q&A on Company’s Final Results - Time:
09:00:07 - Date:
6 Oct 2020 - Category:
Corporate updates - ID:
2192B
6 October 2020
Physiomics plc
("Physiomics" or "the Company")
Presentation and Q&A on Company's Final Results for the year ended 30 June 2020
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, yesterday made a presentation regarding its final results for the year ended 30 June 2020, using the Investor Meet Company platform. The slide deck used in the presentation can be accessed on our website https://www.physiomics.co.uk/wp-content/uploads/2020/10/Physiomics-Update-30-Sept-2020-vfinalr.pdf and a recording of the presentation, together with the subsequent Q&A, can be viewed by registering or logging on to Investor Meet Company at:
https://www.investormeetcompany.com/physiomics-plc/register-investor.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.
For more information please visit:
www.linkedin.com/company/physiomics-plc/
Presentation and Q&A on Company’s Final Results09:00:076 Oct 2020Corporate updates2192B